Effect of the CD14 promoter polymorphism on liver function tests and its association with alcohol and obesity

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 12, 2003, Pages 1317-1322

  Poullis, Andrew P ^a,b   Shetty, Ajeya K ^a   Risley, Paul D ^b   Collinson, Paul O ^b   Mendall, Michael A ^a  

^a MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CD14; Endotoxin; Fatty liver; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; GENERAL PRACTITIONER; GENETIC POLYMORPHISM; HUMAN; LIVER FUNCTION; MALE; NORMAL HUMAN; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION;

AGED; AGING; ALANINE TRANSAMINASE; ALCOHOL DRINKING; ANTIGENS, CD14; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 3943093209     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200312000-00010     Document Type: Article

References (25)

1. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112-117.
2. Reid AE. Non-alcoholic steatohepatitis. Gastroenterology 2001; 121:710-723.
3. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29:495-501.
4. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433.
5. Goyert SM, Ferrero E. Biochemical analysis of myeloid antigens and cDNA expression of gp55 (CD14). In: McMichael A. (editor): Leucocyte Typing III. Oxford: Oxford University Press; 1987, pp. 613-619.
6. Matsuura K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med 1994; 179:1671-1676.
7. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 1993; 14:121-125.
8. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002; 282:1-5.
9. Zhang DE, Hetherington CJ, Tan S, Dziennis SE, Gonzalez DA, Chen HM, et al. Sp1 is a critical factor for the monocytic specific expression of human CD14. J Biol Chem 1994; 269:11425-11434.
10. Hubacek JA, Rothe G, Pit'ha J, Skodova V, Poledne R, Schmitz G. C→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99:3218-3220.
11. Jarvelainen HA, Orpana A, Perola M, Savolainen VT, Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33:1148-1153.
12. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20:976-983.
13. Karhukorpi J, Yan Y, Niemela S, Valtonen J, Koistinen P, Joensuu T, et al. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol 2002; 128:326-332.
14. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001; 167:5838-5844.
15. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108:485-493.
16. Hiki N, Berger D, Mimura Y, Frick J, Dentener MA, Burman WA, et al. Release of endotoxin-binding proteins during major elective surgery: role of soluble CD14 in phagocytic activation. World J Surg 2000; 24:499-506.
17. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312:1061-1065.
18. Fried SK, Zechner R. Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity. J Lipid Res 1989;30:1917-1923.
19. Matsuoka M, Pham NT, Tsukamoto H. Differential effects of interleukin-1 alpha, tumor necrosis factor alpha, and transforming growth factor beta 1 on cell proliferation and collagen formation by cultured fat-storing cells. Liver 1989; 9:71-78.
20. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26:143-146.
21. Perrett AD, Higgins G, Johnston HH, Massarella GR, Truelove SC, Wright R. The liver in Crohn's disease. Q J Med 1971; 40:187-209
22. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
23. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
24. Li XM, Jeffers LJ, Reddy KR, de Medina M, Silva M, Villanueva S, et al. Immunophenotyping of lymphocytes in liver tissue of patients with chronic liver diseases by flow cytometry. Hepatology 1991; 14:121-127
25. Rey Nores JE, Bensussan A, Vita N, Stelter F, Arias MA, Jones M, et al. Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol 1999; 29:265-276.